GRI Bio Business Summary

GRI Bio, Inc. (GRI) is a clinical-stage biopharmaceutical company that operates as a pre-revenue developer of novel immunotherapies, generating capital primarily through public equity offerings—such as its $6.5 million "at-the-market" (ATM) facility raised in January 2026—and strategic private placements to fund its research and development. The company’s business model is centered on the discovery and commercialization of Natural Killer T (NKT) cell modulators designed to interrupt the inflammatory cascade at its onset to restore immune homeostasis. Its primary business segments include its lead program, GRI-0621, an oral iNKT cell inhibitor in Phase 2a/2b development for idiopathic pulmonary fibrosis, and a pipeline of Type 2 NKT agonists like GRI-0803 for autoimmune disorders such as systemic lupus erythematosus. GRI Bio competes with other clinical-stage pharmaceutical firms such as Cadrenal Therapeutics, BioLineRx, and BioCardia, positioning itself as a specialized innovator in the NKT space with a proprietary library of over 500 compounds. The company is led by a founding executive team featuring President and CEO Marc Hertz, PhD, who previously co-founded Multimeric Biotherapeutics and brings extensive experience in immunotherapy commercialization. The technical and clinical leadership includes Co-Founder and Chief Scientific Officer Vipin Kumar Chaturvedi, PhD, and Co-Founder and Chief Medical Officer Albert Agro, PhD, both of whom are recognized experts in immunology and clinical trial management. Financial operations are directed by CFO Leanne Kelly, who joined following the 2023 merger with Vallon Pharmaceuticals and previously held senior roles at OptiNose and KPMG. Notable institutional support and board oversight include Chairman David Szekeres, a veteran of Heron Therapeutics, and major shareholder Joseph E. Payne, the CEO of Arcturus Therapeutics, which maintains a significant equity stake in the firm.